AstraZeneca Sees Further Profit Growth, Lifted by Cancer Drugs
AstraZeneca Plc expects profit to grow further this year, boosted by sales of its cancer drugs as it works to offset a patent expiry of a blockbuster diabetes drug.
By Ashleigh Furlong · Bloomberg Markets
AstraZeneca Plc expects profit to grow further this year, boosted by sales of its cancer drugs as it works to offset a patent expiry of a blockbuster diabetes drug.